Latest & greatest articles for latanoprost

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on latanoprost or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on latanoprost and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for latanoprost

1. Latanoprost + timolol (Fixapost) Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Latanoprost + timolol (Fixapost) Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. Published 13 May 2019 Product update SMC2159 latanoprost 50 micrograms/mL plus timolol 5mg/mL preservative free eye drops (Fixapost®) Thea Pharmaceuticals Limited 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises (...) NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission latanoprost plus timolol (Fixapost®) is accepted for restricted use within NHSScotland. Indication under review: reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. SMC restriction: to use

2019 Scottish Medicines Consortium

2. Latanoprost

Latanoprost Top results for latanoprost - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for latanoprost The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. latanoprost (Monoprost )

latanoprost (Monoprost ) latanoprost | CADTH.ca Find the information you need latanoprost latanoprost Last Updated: May 17, 2018 Result type: Reports Project Number: SR0541-000 Product Line: Generic Name: latanoprost Brand Name: Monoprost Manufacturer: Laboratoires Théa Indications: glaucoma and ocular hypertension Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: April 24, 2018 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

4. Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension

Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development (...) as these outputs are produced as required for our stakeholders. > > > Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension September 2017 Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high pressure in the liquids inside the eye but it can happen when the pressure level is normal. Individuals with consistently high eye pressure are at risk of developing

2017 NIHR Innovation Observatory

5. Latanoprost (Xalatan): increased reporting of eye irritation since reformulation

Latanoprost (Xalatan): increased reporting of eye irritation since reformulation Latanoprost (Xalatan): increased reporting of eye irritation since reformulation - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Latanoprost (Xalatan): increased reporting of eye irritation since reformulation Advise patients to tell their health professional if they experience severe eye irritation. Published 20 July 2015 From: Therapeutic area: When prescribing or dispensing the Xalatan brand (...) of latanoprost: advise patients to tell their health professional if they experience severe eye irritation review treatment if patients mention severe eye irritation please continue to report suspected side effects to latanoprost or any other medicines on a Xalatan is an eye-drop formulation of latanoprost. It is licensed for the reduction of intraocular pressure in adults and children with ocular hypertension and open angle glaucoma. In 2013, the Xalatan pH was reduced from 6.7 to 6.0 to allow for long-term

2015 MHRA Drug Safety Update

6. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. (Full text)

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Treatments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo-controlled trials have assessed visual function preservation, and the observation periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients given latanoprost compared with those given placebo.In (...) this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-angle glaucoma at ten UK centres (tertiary referral centres, teaching hospitals, and district general hospitals). Eligible patients were randomly allocated (1:1) with a website-generated randomisation schedule, stratified by centre and with a permuted block design, to receive either latanoprost 0·005% (intervention group) or placebo (control group) eye drops. Drops were administered from identical bottles

2015 Lancet PubMed

7. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. (Full text)

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Treatments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo-controlled trials have assessed visual function preservation, and the observation periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients given latanoprost compared with those given placebo.In (...) this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-angle glaucoma at ten UK centres (tertiary referral centres, teaching hospitals, and district general hospitals). Eligible patients were randomly allocated (1:1) with a website-generated randomisation schedule, stratified by centre and with a permuted block design, to receive either latanoprost 0·005% (intervention group) or placebo (control group) eye drops. Drops were administered from identical bottles

2014 Lancet PubMed

8. Relative efficacy and safety of preservative-free Latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials

Relative efficacy and safety of preservative-free Latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials Relative efficacy and safety of preservative-free Latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials Relative efficacy and safety of preservative-free Latanoprost (T2345 (...) ) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials Cucherat M, Stalmans I, Rouland JF CRD summary The authors concluded that preservative-free latanoprost (T2345) was better tolerated and no less effective than all other prostaglandin analogues assessed. All comparisons except one were indirect so there was insufficient data from direct comparisons to assess the validity of the indirect comparisons and the authors

2014 DARE.

9. Latanoprost

Latanoprost USE OF LATANOPROST IN PREGNANCY 0344 892 0909 USE OF LATANOPROST IN PREGNANCY (Date of issue: February 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Latanoprost is a prostaglandin analogue used topically in the treatment of ocular hypertension and open-angle glaucoma. Systemic (...) use of prostaglandins can increase uterine tone, have known abortifacient effects, and may also cause reduced placental perfusion to the fetus, raising concerns regarding their use during pregnancy. However, latanoprost is currently only licensed for ocular administration, therefore a high systemic concentration following use would not be expected at the recommended therapeutic dose of 1.5 micrograms/day. There are no large epidemiological studies on the use of latanoprost during pregnancy

2014 UK Teratology Information Service

10. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension (Full text)

Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. CRD summary The study examined the cost-effectiveness of first-line (...) treatment with either latanoprost or timolol for the management of ocular hypertension. The authors concluded that treatment starting with latanoprost was not cost-effective compared with treatment starting with timolol because of small differences in health benefits and the high price of latanoprost. The analysis was based on a valid modelling framework. The authors’ conclusions appear robust. Type of economic evaluation Cost-effectiveness analysis Study objective The study examined the cost

2012 NHS Economic Evaluation Database. PubMed

11. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database (Full text)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment (...) persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Lafuma A, Salmon JF, Robert J, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

2011 NHS Economic Evaluation Database. PubMed

12. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database

Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients (...) in comparison with a fixed combination of latanoprost and timolol (LT) as first-line therapy for ocular hypertension or glaucoma. The authors concluded that first-line treatment with travoprost was maintained longer than LT and halved the cost of care, but differences in the disease severity between the two groups might have affected the validity of these findings. The study had some methodological limitations and caution is required when interpreting the authors’ conclusions. Type of economic evaluation

2009 NHS Economic Evaluation Database.

13. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model (Full text)

Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health (...) economic model Stewart W C, Stewart J A, Mychaskiw M A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the long-term cost-effectiveness of latanoprost versus timolol as monotherapy for the treatment of open

2009 NHS Economic Evaluation Database. PubMed

14. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure

Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure Cheng J W, Wei R L CRD summary This review concluded that bimatoprost is more effective (...) in reducing morning elevated intraocular pressure (IOP) than latanoprost, and at achieving the target IOP at 3 months. Both treatments were generally well tolerated. Given several considerations with the included studies, such as clinical differences between the studies and limitations with the data synthesis, the authors’ conclusions may not be reliable. Authors' objectives To compare the efficacy and tolerability of bimatoprost with latanoprost in treating patients with elevated intraocular pressure

2008 DARE.

15. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Payet S, Denis P, Berdeaux G, Launois R Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the costs and effects of travoprost and latanoprost as single treatments for glaucoma in France. The authors concluded that travoprost was very cost-effective, producing fewer treatment changes, at a small increase in cost, which was acceptable

2008 NHS Economic Evaluation Database.

16. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom

Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis (...) of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Le Pen C, Ligier M, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn

2005 NHS Economic Evaluation Database.

17. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension

A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension Walt J G, Lee J T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of bimatoprost 0.03% QD (BIM) and latanoprost 0.005% QD (LAT) in patients with glaucoma or ocular hypertension (OHT). The drugs were administered into both eyes once daily, in the evening. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population

2004 NHS Economic Evaluation Database.

18. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension

A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension Day D G, Schacknow P N, Sharpe E D, Ellyn J C, Kulze J C, Threlkeld A B (...) , Jones E D, Brown R H, Jenkins J N, Stewart W C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study compared monotherapy with latanoprost 0.005%, bimatoprost 0.03% or topical beta-blockers for the treatment of open-angle

2004 NHS Economic Evaluation Database.

19. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects

Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Halpern M T, Covert D W, Robin A L Record Status This is a critical (...) 100% of the medical visits, in 50% to less than 75% of the visits, or in less than 50% of the visits. The probability of VFD progression was assessed according to the IOP level of the patients, as reported by four different studies. The mean IOP was assessed overall, at baseline and throughout the day, during a 1-year study period for the treatments considered at analysis (travoprost, latanoprost and timolol), as reported by one RCT included in the review. These primary outcomes were included

2002 NHS Economic Evaluation Database.

20. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension

An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular (...) hypertension Stewart W C, Leech J, Sharpe E D, Kulze J, Ellyn J, Day D G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors investigated a switch to latanoprost monotherapy, or the addition of latanoprost or brimonidine

2002 NHS Economic Evaluation Database.